Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
olomorasib
- Development stage
- Phase 3
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Olomorasib is a selective, covalent inhibitor of the KRAS G12C protein, developed by Eli Lilly and Company. It is used for treating cancers such as non-small cell lung cancer (NSCLC) and colorectal cancer. Olomorasib targets the KRAS G12C mutation, inhibiting mutant KRAS-dependent signaling.
- Other names
- 2-amino-4-[(4as)-8-chloro-10-fluoro-2,3,4,4a,5,6-hexahydro-12-oxo-3-(1-oxo-2-propen-1-yl)-1h,12h-pyrazino[2,1-d][1,5]benzoxazocin-9-yl]-7-fluoro-benzo[b]thiophene-3-carbonitrile
02
Targets
KRASG12C (Kirsten rat sarcoma viral oncogene homolog G12C)
Beyond the preview
Go deeper on olomorasib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on olomorasib.